Xenon Pharmaceuticals Inc. (XENE) announced Friday morning that its Phase 2 study of XEN801 in patients with moderate to severe acne did not demonstrate a statistically significant difference from vehicle placebo in its primary endpoint.
from RTT - Before the Bell http://ift.tt/2nXxdAg
via IFTTT
No comments:
Post a Comment